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Osteoporosis is a common, serious disease characterised by a
low bone mass and microarchitectural deterioration resulting
in bone fragility and an increased risk of fracture.1,2 The
mainstay of current therapies for osteoporosis is antiresorptive
agents like calcium and vitamin D, oestrogen, selective
oestrogen receptor modulators (SERMs), the bisphosphonates
and calcitonin.  These drugs inhibit osteoclast-mediated bone
loss, reduce bone turnover (both resorption and formation),
and modestly (less than 10%) increase bone mineral density
(BMD).  They reduce but do not eliminate fracture risk, and do
not restore lost bone structure.3,4 Ideally, antiresorptive drugs
should be employed to prevent osteoporosis, whereas osteo-
anabolic agents, either alone or in combination with
antiresorptives, should be used to treat established disease.
Anabolic agents directly stimulate bone formation by
augmenting osteoblast proliferation and/or inhibition of
osteoblast apoptosis.  They have the potential to increase bone
mass, restore skeletal microarchitecture and reduce fracture
risk to a greater extent than the antiresorptives.  Fluoride was
the first anabolic agent to be used in the treatment of
osteoporosis, followed by growth hormone (GH) and insulin-
like growth factor 1 (IGF-1). More recently, strontium, statins
and parathyroid hormone (PTH) have been added to the list,
with recombinant human PTH emerging as the most promising
osteoanabolic agent to date.
Fluoride
Sodium fluoride markedly stimulates bone formation and
increases axial BMD.  However, randomised controlled trials
employing high fluoride doses (up to 120 mg daily) have
revealed no reduction in vertebral fracture incidence, despite
an impressive increase in BMD.5 Moreover, adverse effects on
the gastrointestinal tract and on cortical bone (a possible
increase in hip fracture risk; lower extremity pain syndrome)
were of concern.  More recent studies, with a lower-dose
enteric-coated formulation of fluoride, have been more
encouraging.6 Combining fluoride and antiresorptive agents
like oestrogen7 or bisphosphonates8 has also yielded more
promising results.  Fluoride, therefore, has the potential to be a
useful drug in the treatment of osteoporosis, but further clinical
trials are necessary before its routine use can be recommended.
GH and IGF-1
Both GH and IGF-1 promote osteoblast proliferation, and low
levels of IGF-1 have been associated with an increased fracture
risk.9 Results of prospective studies are disappointing,
however.10 Changes in BMD have been modest, no fracture
data are available, and treatment is associated with numerous
adverse effects.  Targeting IGF-1 to bone remains the biggest
challenge before the treatment of osteoporosis with this agent
can be realised.
Statins
Studies from Mundy’s group have demonstrated that statins
directly injected into the calvaria of mice result in increased
bone formation, which is mediated by bone morphogenetic
protein 2 (BMP-2), and prevented by mevalonate, a
downstream metabolite of HMG coenzyme A reductase, which
is the rate-limiting step in cholesterol biosynthesis.10 Statins
are, however, almost entirely cleared via first-pass hepatic
metabolism and do not localise to bone.  Animal studies from
our laboratory have confirmed that statins stimulate bone
formation — bone resorption was also stimulated, however,
resulting in a decreased BMD in rodents fed these lipid-lowering
drugs.11 Finally, large clinical studies have failed to show a
clear beneficial effect of statins on fracture risk.12 Further
studies are therefore required to explore the osteoanabolic
potential of these agents.
Strontium
Strontium ranelate appears from animal studies to have a dual
action on skeletal tissue, stimulating osteoblastic bone
formation and inhibiting osteoclastic bone resorption.  Clinical
trials have supported its efficacy and safety.  In a large
randomised placebo-controlled trial involving 1 649
postmenopausal women with at least one vertebral fracture,
strontium ranelate was shown to decrease biochemical markers
of bone resorption, increase markers of formation as well as
BMD, and reduce the relative risk of new vertebral fractures by
41%.13 This agent holds much promise as a new anabolic agent
in the management of osteoporosis.
754
New anabolic agents in the treatment of osteoporosis
Stephen Hough
A dour academic in the Endocrine Unit, Department of Medicine,
University of Stellenbosch, Stephen Hough has spent his entire
life in the shadow of Table Mountain, bar a three-year stint in St
Louis, USA. He is crazy about golf and loves woodwork, jazz,
good food and wine, and the outdoors.
SAMJ Forum  11/4/03  4:31 PM  Page 754
SAMJ FORUM
Parathyroid hormone (PTH)
Continuous exposure to high concentrations of PTH, as occurs
in primary hyperparathyroidism, markedly stimulates
osteoclastic bone resorption and decreases bone mass.
Intermittent, low-dose PTH administration, on the other hand,
causes rapid stimulation of bone formation which results in a
marked increase in bone mass and strength, improvements in
trabecular micro-architecture and cortical geometry, and a
significant reduction in the risk of vertebral as well as non-
vertebral fractures.14-19 Most clinical experience with PTH as an
osteoanabolic agent has been obtained with the amino-terminal
fragment of parathyroid hormone (PTH (1-34) or teriparatide),
which will soon be available as a treatment for osteoporosis in
South Africa.  Clinical studies are also underway with intact
human PTH (1-84), other fragments of PTH and of PTHrP, as
well as calcilytics which stimulate the secretion of endogenous
PTH.
The molecular sequence of events responsible for the
anabolic skeletal effects of PTH remains to be elucidated.  Daily
subcutaneous injection of PTH (1-34) increases the osteoblast
birth rate and prevents osteoblast apoptosis, thereby increasing
the number of osteoblasts and the rate of new bone
formation.14,16 Biochemical markers of bone formation (e.g.
bone alkaline phosphatase, BALP) start to increase within a
few weeks of PTH administration and reach a maximum at 6
months, whereas resorption parameters (e.g. cross-linked N-
telopeptides, NTX) generally begin to rise after 2 - 4 months
and peak at 12 months, thus providing an ‘anabolic window’ of
some 6 - 9 months during which PTH is maximally anabolic.18,19
PTH monotherapy (coupled with calcium and vitamin D
supplementation) has been shown in numerous controlled
trials to increase trabecular spine BMD by approximately 15%
and total hip BMD by some 5%.15-19 PTH in combination with
antiresorptives like oestrogen increases lumbar BMD by nearly
30% and femoral BMD by 11%.20 While most studies have been
performed in postmenopausal women with osteoporosis, PTH
has also been shown to markedly increase BMD in models of
low-turnover osteoporosis — notably in men with
osteoporosis21 and in glucocorticoid-induced osteoporosis.22
PTH not only increases BMD significantly more than current
antiresorptive agents do18,19 but also improves bone size and
microarchitectural deterioration.  The latter includes an
increase in trabecular number, decrease in trabecular spacing
and major improvements in histological indices of trabecular
connectivity, resulting in enhanced bone strength.23-24 Moreover,
although potential PTH-induced loss of cortical bone was of
concern earlier, recent studies have suggested similar anabolic
effects and improved strength of this bone envelope.19
Do improvements in BMD and bone architecture following
PTH administration result in a clinically significant reduction
in fracture rates?  Following a number of smaller studies
suggesting that this was indeed the case, the results of a large
randomised, placebo-controlled trial involving 1 637
postmenopausal women were recently published.17 Compared
with placebo, daily subcutaneous injection of human PTH (1-
34) for as little as 21 months, reduced the risk of new vertebral
fractures by 65 - 70% and non-vertebral fractures by 35 - 40%.
A similar reduction in vertebral fracture rate was also
documented recently in 437 men with osteoporosis.25
Subcutaneous injection of PTH is generally well tolerated in
a trial situation and compliance with treatment has been shown
to be similar to that of patients taking oral bisphosphonates.18
This may very well change in real life — continued adherence
to therapy will require patient education and motivation.  Side-
effects of PTH have been limited to occasional nausea,
headaches and leg cramps.  Mild hypercalcaemia occurs in
some 10% of patients receiving 20 µg PTH daily, but the
incidence of hypercalciuria (urinary calcium excretion
exceeding 7.5 mmol per day) and renal stone disease does not
appear to increase.17 Serum uric acid levels may increase by up
to 20%, but clinical gout is not more prevalent in patients
treated with PTH.  Circulating antibodies to PTH developed in
3 - 8% of subjects, but does not have any discernible effect on
outcomes.17
Certain concerns about PTH still prevail.  It is unclear
whether PTH should ideally be prescribed as monotherapy or
whether it should be combined with an antiresorptive drug.
This is especially true following withdrawal of PTH treatment,
after say 18 - 24 months.  This may also be the case in subjects
with predominantly cortical osteopenia.  Certainly, ample daily
calcium (1 000 mg) and vitamin D (400 - 1 200 IU)
supplementation is mandatory.  Of some concern too is the
tumorigenic potential of PTH.  Long-term studies with high-
dose PTH, administered to 6-week-old Fisher 344 rats, have
demonstrated a dose-related increased risk of osteogenic
sarcoma.26,27 This effect is consistent with lifelong exposure, in a
growing rodent, to high-dose PTH and is unlikely to have
relevance to human bone physiology.  Shorter or lower-dose
exposure to PTH has not resulted in the development of
osteosarcomas or other bone tumours.  All primate studies
have failed to show a similar association and osteogenic
sarcomas have not been noted with increased frequency in
patients with primary hyperparathyroidism or in any of the
clinical trials performed in over 2 500 patients treated with
PTH (1-34) for up to 3 years.19,27 It is, therefore, reasonable to
conclude that PTH is safe in human subjects, although on-
going safety data need to be collated.
As mentioned earlier, PTH (1-34) will soon be available as a
treatment option for osteoporosis in South Africa.  The local
cost of this product will undoubtedly be high and serious
ethical dilemmas will once again be posed with regard to the
allocation of expensive resources.  Clear indications for its use
(e.g. antiresorptive therapy failue; very low prevalent BMD;
high fracture risk score), close audit of its appropriate and cost-
effective utilisation, and every effort to make this valuable drug
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available to all (including differential drug pricing in the
private and public health sectors) will go a long way towards
optimising the management of osteoporosis in this country.
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